Foreseen Biotechnology was founded in 2021 by a team of returning scholars with expertise in proteomics and experience at major international pharmaceutical companies. The company builds a cutting-edge proteomics platform aimed at unmet clinical needs, designing patient cohorts to collect high-quality, multi-dimensional proteomic data, integrated with other omics analyses to accelerate discovery of biomarkers and novel therapeutic targets. ByDrug+1 On the diagnostics side, Foreseen has initiated registration for its first chemiluminescent IVD product and is developing industry-lab joint LDT solutions; therapeutically, it is developing projects such as the antibody-drug conjugate (ADC) FS001 via global licensing or collaboration. Global+1 Its work spans areas including oncology, inflammation/autoimmune disease, and neurological disorders.